Knight Therapeutics Inc. (GUD.TO)
CAD 5.21
(-0.19%)
CAD 5.21
(-0.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.83 Million CAD | 43.68% |
| 2022 | -29.89 Million CAD | -290.7% |
| 2021 | 15.67 Million CAD | -50.65% |
| 2020 | 31.76 Million CAD | 118.78% |
| 2019 | 14.51 Million CAD | -39.71% |
| 2018 | 24.07 Million CAD | 39.64% |
| 2017 | 17.24 Million CAD | -7.09% |
| 2016 | 18.56 Million CAD | -45.68% |
| 2015 | 34.16 Million CAD | -72.85% |
| 2014 | 125.85 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.94 Million CAD | 57.28% |
| 2024 Q1 | -4.54 Million CAD | 81.31% |
| 2023 Q2 | 1.84 Million CAD | 146.74% |
| 2023 FY | -16.83 Million CAD | 43.68% |
| 2023 Q4 | -24.32 Million CAD | -353.71% |
| 2023 Q3 | 9.58 Million CAD | 421.09% |
| 2023 Q1 | -3.93 Million CAD | 74.08% |
| 2022 Q2 | 2.51 Million CAD | 113.38% |
| 2022 FY | -29.89 Million CAD | -290.7% |
| 2022 Q4 | -15.18 Million CAD | -1054.62% |
| 2022 Q3 | 1.59 Million CAD | -36.76% |
| 2022 Q1 | -18.81 Million CAD | -126.61% |
| 2021 Q2 | 29 Million CAD | 715.18% |
| 2021 Q1 | 3.55 Million CAD | -56.78% |
| 2021 Q4 | -8.3 Million CAD | 3.32% |
| 2021 FY | 15.67 Million CAD | -50.65% |
| 2021 Q3 | -8.58 Million CAD | -129.6% |
| 2020 Q2 | 17.44 Million CAD | 1121.01% |
| 2020 FY | 31.76 Million CAD | 118.78% |
| 2020 Q3 | 18.09 Million CAD | 3.7% |
| 2020 Q4 | 8.23 Million CAD | -54.5% |
| 2020 Q1 | -1.7 Million CAD | 74.37% |
| 2019 Q2 | 18.95 Million CAD | 265.31% |
| 2019 Q1 | 5.18 Million CAD | 2247.96% |
| 2019 Q4 | -6.66 Million CAD | -125.38% |
| 2019 FY | 14.51 Million CAD | -39.71% |
| 2019 Q3 | -2.95 Million CAD | -115.61% |
| 2018 FY | 24.07 Million CAD | 39.64% |
| 2018 Q4 | 221 Thousand CAD | -98.29% |
| 2018 Q2 | 4.01 Million CAD | -41.83% |
| 2018 Q1 | 6.9 Million CAD | -3.3% |
| 2018 Q3 | 12.93 Million CAD | 221.72% |
| 2017 Q3 | 3.59 Million CAD | 682.79% |
| 2017 Q2 | 459 Thousand CAD | -92.41% |
| 2017 Q1 | 6.04 Million CAD | -23.83% |
| 2017 FY | 17.24 Million CAD | -7.09% |
| 2017 Q4 | 7.14 Million CAD | 98.86% |
| 2016 FY | 18.56 Million CAD | -45.68% |
| 2016 Q1 | 477 Thousand CAD | -91.41% |
| 2016 Q4 | 7.93 Million CAD | 39.33% |
| 2016 Q2 | 4.44 Million CAD | 832.08% |
| 2016 Q3 | 5.69 Million CAD | 28.16% |
| 2015 Q3 | 6.27 Million CAD | -26.33% |
| 2015 Q4 | 5.55 Million CAD | -11.52% |
| 2015 FY | 34.16 Million CAD | -72.85% |
| 2015 Q1 | 13.81 Million CAD | -88.95% |
| 2015 Q2 | 8.52 Million CAD | -38.33% |
| 2014 Q4 | 124.98 Million CAD | 22138.69% |
| 2014 Q3 | 562 Thousand CAD | 43.87% |
| 2014 Q2 | 390.61 Thousand CAD | 615.72% |
| 2014 Q1 | -75.74 Thousand CAD | 0.0% |
| 2014 FY | 125.85 Million CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | 400.43 Thousand CAD | 0.0% |
| 2012 Q3 | 56.92 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -69.32 Million CAD | 75.716% |
| Avicanna Inc. | -8.74 Million CAD | -92.554% |
| Avant Brands Inc. | -5.07 Million CAD | -232.051% |
| Cardiol Therapeutics Inc. | -28.12 Million CAD | 40.149% |
| Crescita Therapeutics Inc. | -1.98 Million CAD | -747.684% |
| MediPharm Labs Corp. | -13.08 Million CAD | -28.678% |
| OrganiGram Holdings Inc. | -229.47 Million CAD | 92.664% |
| Canopy Growth Corporation | -657.26 Million CAD | 97.439% |
| Willow Biosciences Inc. | -13.02 Million CAD | -29.212% |
| Auxly Cannabis Group Inc. | -44.51 Million CAD | 62.178% |